Phaseline

Targets › CD22

CD22 (B-cell receptor CD22): drug programs, companies and trials

37 programs from 30 companies in 67 trials: 38 Phase 1, 25 Phase 2, 4 Phase 3; Oncology; next expected readout Dec 2026.

Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. (UniProt, P20273)

Open in Phaseline: the race on CD22, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Zhejiang UniversityCD19/CD22 CAR-T cells
Bispecific CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 2Large B-Cell Lymphoma (LBCL); ALLDec 2026
Beijing Tongren HospitalCD19/CD22-bispecific CAR-T cells
bispecific CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 2B-cell Acute Lymphoblastic LeukemiaDec 2026
Liping DouCD22/CD19 CAR-T cell immunotherapy
Dual-targeted CAR-T cell therapy against CD19 and CD22
CD22, CD19Phase 2LymphomaJan 2027
Daihong LiuCD22/CD19 CAR-T cell immunotherapy
CAR-T cell therapy targeting CD22 and CD19
CD22, CD19Phase 2LymphomaMar 2027
Institute of Hematology & Blood Diseases Hospital, ChinaCAR-T cells (single-target or dual-target directed against CD19, CD20, and/or CD
CAR-T cell therapy targeting CD19, CD20, and/or CD22
CD19, CD20, CD22Phase 2Relapsed or Refractory Aggressive B-cell LymphomaMay 2027
The First Affiliated Hospital of Soochow UniversityCD22/CD19 CAR-T cells
Dual-target CAR-T cells directed against CD22 and CD19 with 4-1BB co-stimulatory molecule
CD22, CD19Phase 2B-cell Acute Lymphoblastic LeukemiaJul 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCD19&CD22 bispecific CAR-T cells
Bispecific CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 2B-cell Acute Lymphoblastic Leukemia; B-Cell Lymphoblastic Leukemia/LymphomaDec 2027
National Cancer Institute (NCI)CD22 CAR-transduced T cells
Anti-CD22 CAR-T cell therapy
CD22Phase 2Acute Lymphoblastic LeukemiaJan 2030
PfizerInotuzumab ozogamicin
CD22 binding agent
CD22Phase 2ACUTE LYMPHOBLASTIC LEUKEMIA; B Acute Lymphoblastic Leukemia; B-Cell Acute Lymphoblastic Leukaemia; Leukemia, Acute Lymphoblastic …May 2033
University of Colorado, DenverCD19x22 CAR T Cells
Dual-targeted CAR T cell therapy against CD19 and CD22
CD19, CD22Phase 1Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic LeukemiaDec 2026
Rong TaoKQ-2002 CAR-T cells
anti-CD19/CD22 CAR-T cell therapy
CD19, CD22Phase 1Acute Lymphoblastic Leukemia, in RelapseDec 2026
Beijing GoBroad HospitalDonor-derived CD22 CAR T cells
CAR-T cell therapy targeting CD22
CD22Phase 1B-cell Acute Lymphoblastic LeukemiaDec 2026
Ohio State University Comprehensive Cancer CenterAutologous Anti-CD19/CD20/CD22 CAR T-cells
Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22
CD19, CD20, CD22Phase 1Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveDec 2026
Liping DouCD22/CD19 Dual-Target CAR-T Cells
Dual-target CAR-T cell therapy targeting CD22 and CD19 antigens
CD22, CD19Phase 1B-cell Acute Lymphoblastic LeukemiaDec 2026
Peking University People's HospitalNanobody-Based CD19/CD22 Tandem Dual CAR-T
Nanobody-based dual CAR-T cells targeting CD19 and CD22
CD19, CD22Phase 1Precursor B-Cell Lymphoblastic Leukemia-LymphomaDec 2026
Essen BiotechEB-BH2024 (CD19/CD22-CAR T cells)
CD19/CD22-targeted chimeric antigen receptor T cells
CD19, CD22Phase 1Acute Lymphoblastic Leukemia, Adult B-CellFeb 2027
Stanford UniversityCD22CART
anti-CD22 CAR-T cell therapy
CD22Phase 1Leukemia; Follicular LymphomaFeb 2027
University Hospital TuebingenMB-CART2219.1
CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 1LymphomaMar 2027
Hebei Senlang BiotechnologyAutologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
Multi-target CAR-T cells targeting CD19, CD20, and CD22
CD19, CD22, CD20Phase 119 and 22+ B Cell Hematologic TumorsMar 2027
Sheba Medical CenterSHB-04-CD22
anti-CD22 CAR-T cell therapy
CD22Phase 1B Cell MalignanciesApr 2027
Sumithira VasuAnti-CD19/CD20/CD22 CAR T-Cells
Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22
CD19, CD20, CD22Phase 1Recurrent Acute Lymphoblastic LeukemiaJul 2027
National Cancer Institute (NCI)CD19/CD22-CAR-transduced T cells
bicistronic CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 1B-NHLJul 2027
CellectisUCART20x22
Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptor
CD20, CD22Phase 1B-cell Non-Hodgkin Lymphoma (B-NHL)Aug 2027
Guangzhou Women and Children's Medical CenterCD19/CD22 CAR-T cell therapy
Dual-target CAR-T cell therapy targeting CD19 and CD22 using retroviral vector-based tande
CD19, CD22Phase 1Acute Lymphoblastic LeukemiaDec 2027
Ruijin HospitalAnti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells
Dual-targeted CAR-T cells expressing chimeric antigen receptors against CD19 and CD22
CD19, CD22Phase 1B-cell Acute Lymphoblastic LeukemiaMar 2028
AstraZenecaAZD4512
anti-CD22 antibody-drug conjugate
CD22Phase 1B-cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia (B-ALL)Jul 2028
National University Hospital, SingaporeCD22 CAR T
CAR-T cell therapy targeting CD22 expressing B cell lymphoma cells
CD22Phase 1B-cell Lymphoma RefractoryOct 2028
National Cancer Institute (NCI)Moxetumomab Pasudotox-tdfk
CD22-directed recombinant immunotoxin (anti-CD22 antibody conjugated to Pseudomonas exotox
CD22Phase 1Hairy Cell LeukemiaJun 2029
St. Jude Children's Research HospitalCD19-CD22 CAR T cell
bispecific CAR T cell targeting CD19 and CD22
CD19, CD22Phase 1Acute Lymphoblastic LeukemiaJan 2030
Instituto de Investigación Hospital Universitario La PazAutologous CD19/CD22 CAR T cells
Anti-CD19/CD22 chimeric antigen receptor T cell therapy
CD19, CD22Phase 1Precursor Cell Lymphoblastic Leukemia-LymphomaJun 2030
Umoja BiopharmaUB-VV400
CD22-directed CAR T cell therapy
CD22Phase 1Lymphoma, B CellAug 2031
Seattle Children's HospitalPatient-derived CD19- and CD22 specific CAR T-cells
Dual-specificity CAR-T cells targeting CD19 and CD22
CD19, CD22Phase 1LeukemiaMar 2035
Stanford UniversityCD19/CD22 Chimeric Antigen Receptor T-Cell Therapy
CAR T cell therapy targeting CD19 and CD22
CD19, CD22Phase 1B Acute Lymphoblastic LeukemiaAug 2035
National Cancer Institute (NCI)CD22CART cell infusion
anti-CD22 chimeric antigen receptor T cell therapy
CD22Phase 1Hairy Cell LeukemiaDec 2036
Seattle Children's HospitalSCRI-CAR22v2
anti-CD22 CAR-T cell therapy
CD22Phase 1LeukemiaFeb 2040
Melody SmithAllogeneic donor-derived CD19/CD22-CAR T cells
bivalent CAR-T cell therapy targeting CD19 and CD22
CD19, CD22Phase 1Lymphoid LeukemiaDec 2045
CellectisUCART22
Allogeneic engineered T-cells expressing anti-CD22 chimeric antigen receptor (CAR-T)
CD22Phase 1B-cell Acute Lymphoblastic Leukemia–

Conditions

B-cell Acute Lymphoblastic Leukemia (11) Acute Lymphoblastic Leukemia (6) B Acute Lymphoblastic Leukemia (6) Lymphoma (4) Leukemia (4) ALL (2) Hairy Cell Leukemia (2) Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) Acute Lymphocytic Leukemia (2) Large B-Cell Lymphoma (LBCL) (1) Lymphoid Leukemia (1) Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1)

Modalities

other (17), mixed (11), protein or peptide (4), small molecule (3)

Companies

National Cancer Institute (NCI) (4) Liping Dou (2) Stanford University (2) Cellectis (2) Seattle Children's Hospital (2) Zhejiang University (1) Guangzhou Women and Children's Medical Center (1) Melody Smith (1) Peking University People's Hospital (1) AstraZeneca (1) Sheba Medical Center (1) Beijing Tongren Hospital (1) Institute of Hematology & Blood Diseases Hospital, China (1) Pfizer (1) University of Colorado, Denver (1) St. Jude Children's Research Hospital (1) Umoja Biopharma (1) The First Affiliated Hospital of Soochow University (1) Sumithira Vasu (1) Rong Tao (1)

Related targets

CD19 (24) CD20 (5)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.